What types of cancer is Platinib mainly used to treat?

Pralsetinib is a targeted therapy drug mainly used to treat cancer patients carrying RET gene fusion mutations. RETGene fusion is a driver mutation that may cause continued growth of tumor cells. Platinib selectively inhibits the activity of RET kinase and blocks the signaling pathways of cancer cells, thereby inhibiting the growth and spread of tumors. This mechanism enables it to demonstrate significant efficacy in the treatment of a variety of RET-related cancers.

Currently, platinib is most commonly used to treat RETfusion-positive non-small cell lung cancer (NSCLC). Patients with this type of lung cancer usually have poor responses to traditional chemotherapy, and platinib can specifically target RET fusion mutations to provide a more targeted treatment. Clinical trials have shown that platinib has a high objective response rate and relatively mild side effects in these patients, making it an effective and well-tolerated treatment option.

In addition to non-small cell lung cancer, platinib is also used to treat RETmutated medullary thyroid cancer (MTC) and RETfusion-positive papillary thyroid cancer (PTC). Platinib offers new therapeutic hope for patients with advanced or unresectable disease. Especially for thyroid cancer patients who are ineffective in traditional radioactive iodine treatment, the emergence of RET targeted drugs has greatly improved the treatment prospects.

In general, platinib, as a RET targeted inhibitor, fills the gap in RET related tumor treatment. With the popularization of genetic testing technology, more and more patients can confirm the presence of RET gene mutations through accurate diagnosis and receive personalized treatment. In the future, platinib may also play a broader role in other RET-related tumor types.

Reference materials:https://gavreto.com/